ICUNasdaqSurgical & Medical Instruments & ApparatusUS GAAP · USD

SeaStar Medical Holding Corp

SeaStar Medical Holding Corp is a U.S.-based medical device company focused on therapies that treat acute and chronic kidney injury through selective cytopheretic devices. Its commercial product, QUELIMMUNE, is used in pediatric patients, while the company also develops an adult SCD program and next-generation device candidates.

Revenue1.2m USD
+814.1 %y/y
Operating profit (EBIT)-12.2m USD
+31.8 %y/y
EBIT margin-986.6%
+12,229.7 ppy/y
Net income-12.2m USD
+51.1 %y/y

Fiscal year 2025 · change from previous year

Development 2021–2025

-20-15-10-505m USD2021: EBIT -1.1 m USD20212022: EBIT -12 m USD20222023: EBIT -14 m USD20232024: 0.14 m USD2024: EBIT -18 m USD20242025: 1.2 m USD2025: EBIT -12 m USD20251.2-12
RevenueOperating profit (EBIT)

Business

Share of revenue
Commercial medical devices60 %

Commercialized QUELIMMUNE devices sold for pediatric use in hospital settings.

Clinical-stage device development30 %

Adult SCD and next-generation SCD programs under clinical and regulatory development.

Grants and collaboration revenue10 %

Government grants and potential partner payments that support research and development.

Customers

SeaStar Medical sells primarily to pediatric hospital customers that use QUELIMMUNE in clinical care settings. Its development pipeline is aimed at hospitals and clinicians treating adult patients with serious kidney injury, with future commercialization dependent on regulatory approval and adoption by medical centers.

Pediatric hospital customers

Hospitals and pediatric care centers buying QUELIMMUNE for treated pediatric patients.

Clinical trial and research partners

Sites and institutions supporting adult SCD studies and regulatory development.

Government and grant providers

Public and other grant sources funding research, development, and operations.

Potential collaboration partners

Companies or institutions that may provide license, collaboration, or strategic payments.

Strategy

The company’s near-term strategy is to expand QUELIMMUNE adoption in pediatric hospitals and build a repeatable commercial base. In parallel, it is advancing the adult SCD program through pivotal clinical development and seeking additional capital, collaborations, and grants to support the pipeline.

Commercialize QUELIMMUNE in pediatric hospitalsShort term

Commercial sales are the first scalable product revenue source.

Advance adult SCD regulatory developmentMedium term

Adult approval would materially expand the market beyond pediatrics.

Secure external funding and partnershipsShort term

Development and commercialization require ongoing capital support.

Geography

SeaStar Medical is headquartered in the United States and its reported commercial activity is centered there. The company’s customer base, clinical development work, and regulatory interactions are also U.S.-based, so its business is tied closely to FDA approval pathways and U.S. hospital adoption.

Risks

SeaStar Medical faces substantial financing and going-concern risk because it is still building commercial revenue while funding clinical development. Its business also depends on regulatory outcomes, hospital adoption, and successful execution of clinical trials, all of which can delay or prevent future product sales.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Going concern and financing dependence1Regulatory approval risk2Clinical development risk3
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Going concern and financing dependenceImpact: CriticalLikelihood: High

    The company states it needs additional capital to fund operations and may need restructuring if financing is unavailable.

    ExposureOperationsClinical developmentCommercialization
  2. Regulatory approval riskImpact: HighLikelihood: High

    Adult SCD commercialization depends on successful clinical development and FDA approval.

    Exposure: Adult SCD pipeline

  3. Clinical development riskImpact: HighLikelihood: High

    Preclinical and pivotal trial programs are costly and may fail to demonstrate efficacy or safety.

    Exposure: Adult and next-generation SCD programs

  4. Commercial rollout riskImpact: High

    QUELIMMUNE sales depend on hospital adoption and can fluctuate quarter to quarter.

    Exposure: Pediatric hospital sales

Accounting

Judgemental items
Revenue recognition for QUELIMMUNE sales

Commercial revenue is newly recognized and likely point-in-time based on shipment or delivery terms.

Impact: Affects reported revenue timing and quarterly comparability

Grant revenue recognition

Historical revenue has been primarily from government and other grants.

Impact: Can create non-product revenue that is less repeatable

Stock-based compensation

Clinical and medical affairs employees receive stock-based compensation.

Impact: Raises operating expenses and affects loss metrics

Going-concern and liquidity estimates

Management must assess funding sufficiency and disclosure of substantial doubt.

Impact: Influences financial statement presentation and risk disclosure

Publicly listed companies with a comparable business focus.

Last updated: 24/09/2026